Applications of DLK1 gene, siRNA (small interference Ribonucleic Acid), BM-MSCs (Bone Marrow Mesenchymal Stem Cells) and FGF2 (Fibroblast Growth Factor2)

A gene and application technology, applied in the field of liver fibrosis treatment, can solve unclear problems, achieve the effect of reducing the degree of liver fibrosis, reducing the level of liver fibrosis, and inhibiting the activation of HSC

Inactive Publication Date: 2011-01-12
ZHEJIANG UNIV
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether DLK1 is involved in the process of liver fibrosis in chronic liver disease is still unclear.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of DLK1 gene, siRNA (small interference Ribonucleic Acid), BM-MSCs (Bone Marrow Mesenchymal Stem Cells) and FGF2 (Fibroblast Growth Factor2)
  • Applications of DLK1 gene, siRNA (small interference Ribonucleic Acid), BM-MSCs (Bone Marrow Mesenchymal Stem Cells) and FGF2 (Fibroblast Growth Factor2)
  • Applications of DLK1 gene, siRNA (small interference Ribonucleic Acid), BM-MSCs (Bone Marrow Mesenchymal Stem Cells) and FGF2 (Fibroblast Growth Factor2)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Preparation of chronic liver injury mouse model and detection of DLK1 expression

[0046] Utilize 10% (volume concentration) carbon tetrachloride (solvent is olive oil) to induce chemical liver damage to the ICR mice (about 30 grams of body weight) of mouse age of eight weeks, each mouse is intraperitoneally injected 0.25ml 10% CCl 4 , 2 times a week, continuous injection for 4 weeks, to establish the liver fibrosis model, and the injected mice were fed normally in a sterile environment.

[0047] Extract the total protein from the liver of normal mice, 2 days after injury, 1, 2, 3 and 4 weeks, and detect the expression of DLK1 by Western blot: take 50 μg of protein as a sample, run SDS-PAGE electrophoresis; plain film) for 2 hours; according to 0.1ml / cm 2 Add blocking solution to the membrane area, that is, 2% BSA (2g BSA dissolved in 100ml PBST, wherein PBST is PBS plus 0.05% (volume ratio) TWEEN20), shake gently at room temperature for 2 hours; discard the...

Embodiment 2

[0049] Example 2: In vitro experiments prove that DLK1 promotes HSC activation

[0050] Separation and culture of HSC cells: Normal mouse liver, perfused with collagenase-pronase, collected individual dispersed hepatocytes, carefully added the cell suspension to 8.2% Nycodenz (Axis-shield), centrifuged at 800g for 25 minutes, and collected the middle layer of HSC cells , IMDM (supplemented with 10% FBS and 1% penicillin / streptomycin) 37°C, 5% CO 2 Conditioned cultivation.

[0051] DLK1 protein preparation: clone the extracellular region and signal peptide of DLK1 gene and adjacent 1-3 EGF-like structures; insert the cloned fragment into the vector pCDNA6; transfect HEK293 cells with liposome 2000; collect without serum after 72 hours of transfection The cell supernatant was centrifuged at 500g for 10min; the expressed protein was detected by western blot; the protein expressed in the extracellular region was DLK1 large fragment (DLK1-L) free protein, and the protein expressed...

Embodiment 3

[0058] Example 3: siRNA inhibits DLK1 expression, reduces HSC activation and liver fibrosis

[0059] The above-mentioned liver fibrosis model mice, CCl 4 In the second week of injection, siRNA against DLK1 was injected into the tail vein, and the sequence was:

[0060] 5'-P.CCCUAUUAAUGCAUGAUAAdTdT-3' (forward), SEQ ID NO: 1;

[0061] 5'-P.UUAUCAUGCAUUAAUAGGGAG-3' (reverse) SEQ ID NO:2.

[0062] Synthesized by Shanghai Gemma Pharmaceutical Technology Co., Ltd.

[0063] 50μg siRNA dissolved in 1ml PBS was quickly injected through the tail vein, and then each mouse was injected again 8 hours and 24 hours later (50μg siRNA); at the same time, other mice with the same injury were injected with 1ml PBS as a control. Afterwards, all mice were subjected to liver injury according to the above method for 2 weeks, and the liver tissue of the mice was taken, and a part of the total RNA was extracted with TRizol (Invetigen). The extraction method was carried out according to the instruc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of a DLK1 gene as a target spot for curing hepatic fibrosis-renal tubular ectasia syndrome; namely the DLK1 gene is used as the target spot for designing a relevant medicine to reduce DLK1 expression and inhibit hepatic stellate cell activation so as to reduce the hepatic fibrosis-renal tubular ectasia syndrome. The invention also discloses applications of siRNA, bone marrow mesenchymal stem cells and cell factors FGF2 to preparing the medicine for curing the hepatic fibrosis-renal tubular ectasia syndrome.

Description

technical field [0001] The invention relates to the field of liver fibrosis treatment, in particular to the use of DLK1 as a target in the treatment of liver fibrosis. Background technique [0002] Hepatitis, liver metabolic diseases, and the resulting liver fibrosis and cirrhosis are common clinical diseases. In recent years, surveys have shown that the number of deaths caused by liver diseases has increased year by year, and various liver diseases have become an important reason that affects human life expectancy. There is still a lack of ideal treatment for liver disease, and about 10% of patients eventually die of liver failure. At present, maintenance and supportive therapy are adopted for various acute and chronic liver diseases; orthotopic liver transplantation is expensive due to lack of donor livers, and there are still immune rejection problems, so its clinical value is limited and there are very few beneficiaries; bioartificial liver and hepatocytes Transplantati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K48/00A61K35/28A61K38/19A61K31/713C12N15/11A61P1/16
Inventor 邵健忠潘若浪项黎新王萍董伟仁
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap